Yvon ES - Search Results

1

CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma.

Balakrishnan PB, Ledezma DK, Cano-Mejia J, Andricovich J, Palmer E, Patel VA, Latham PS, Yvon ES, Villagra A, Fernandes R, Sweeney EE. Balakrishnan PB, et al. Among authors: yvon es. Nano Res. 2022 Mar;15(3):2300-2314. doi: 10.1007/s12274-021-3813-1. Epub 2021 Oct 12. Nano Res. 2022. PMID: 36089987 Free PMC article.

2

Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.

Burga RA, Yvon E, Chorvinsky E, Fernandes R, Cruz CRY, Bollard CM. Burga RA, et al. Clin Cancer Res. 2019 Jul 15;25(14):4400-4412. doi: 10.1158/1078-0432.CCR-18-3183. Epub 2019 Apr 22. Clin Cancer Res. 2019. PMID: 31010834 Free PMC article.

3

Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia.

Raskin S, Van Pelt S, Toner K, Balakrishnan PB, Dave H, Bollard CM, Yvon E. Raskin S, et al. Mol Ther Methods Clin Dev. 2021 Oct 1;23:296-306. doi: 10.1016/j.omtm.2021.09.008. eCollection 2021 Dec 10. Mol Ther Methods Clin Dev. 2021. PMID: 34729377 Free PMC article.

4

Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.

Burga RA, Nguyen T, Zulovich J, Madonna S, Ylisastigui L, Fernandes R, Yvon E. Burga RA, et al. Cytotherapy. 2016 Nov;18(11):1410-1421. doi: 10.1016/j.jcyt.2016.05.018. Epub 2016 Jul 12. Cytotherapy. 2016. PMID: 27421740 Review.

5

Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.

Yvon ES, Burga R, Powell A, Cruz CR, Fernandes R, Barese C, Nguyen T, Abdel-Baki MS, Bollard CM. Yvon ES, et al. Cytotherapy. 2017 Mar;19(3):408-418. doi: 10.1016/j.jcyt.2016.12.005. Epub 2017 Jan 19. Cytotherapy. 2017. PMID: 28109751

6

RNA polymerase II pausing factor NELF in CD8⁺ T cells promotes antitumor immunity.

Wu B, Zhang X, Chiang HC, Pan H, Yuan B, Mitra P, Qi L, Simonyan H, Young CN, Yvon E, Hu Y, Zhang N, Li R. Wu B, et al. Nat Commun. 2022 Apr 20;13(1):2155. doi: 10.1038/s41467-022-29869-2. Nat Commun. 2022. PMID: 35444206 Free PMC article.

7

Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.

Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, Dotti G, Brenner MK. Yvon E, et al. Clin Cancer Res. 2009 Sep 15;15(18):5852-60. doi: 10.1158/1078-0432.CCR-08-3163. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737958 Free PMC article.

8

Gene Modification of Human Natural Killer Cells Using a Retroviral Vector.

Kellner JN, Cruz CR, Bollard CM, Yvon ES. Kellner JN, et al. Among authors: yvon es. Methods Mol Biol. 2016;1441:203-13. doi: 10.1007/978-1-4939-3684-7_17. Methods Mol Biol. 2016. PMID: 27177668

9

Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization.

Powell AB, Yadavilli S, Saunders D, Van Pelt S, Chorvinsky E, Burga RA, Albihani S, Hanley PJ, Xu Z, Pei Y, Yvon ES, Hwang EI, Bollard CM, Nazarian J, Cruz CRY. Powell AB, et al. Among authors: yvon es. J Transl Med. 2019 Sep 23;17(1):321. doi: 10.1186/s12967-019-2055-4. J Transl Med. 2019. PMID: 31547819 Free PMC article.

10

Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. Parmar S, et al. Cytotherapy. 2014 Jan;16(1):90-100. doi: 10.1016/j.jcyt.2013.07.009. Epub 2013 Oct 26. Cytotherapy. 2014. PMID: 24480547 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page